Background and aims: We recently identified lysosomal acid lipase (LAL) deficiency, a recessive disease caused by mutations in LIPA, in 3 patients with a clinical diagnosis of familial hypercholesterolemia (FH). We aimed to determine the prevalence of LIPA mutations among individuals with a clinical FH diagnosis. Methods: In 276 patients with phenotypic FH, in whom no genetic basis for their phenotype was found, LIPA was sequenced. All variants were assessed for pathogenicity using a literature search and in silico prediction models. Results: We included 213 adults and 63 children with mean (±SD) LDL-C levels of 7.8 ± 1.3 and 4.4 ± 1.5 mmol/L, respectively. Twenty-one variants were identified. Six patients were heterozygous carrier of a (potentially) pathogenic mutation. No homozygous LIPA mutation carriers were identified. Conclusions: Our data show that LAL deficiency was not missed as diagnosis in our study population but the frequency of heterozygous LIPA mutations implies that the FH population might be relatively enriched with LIPA mutation carriers.
Introduction
Lysosomal acid lipase (LAL) deficiency is a rare recessive lysosomal storage disease caused by mutations in LIPA (OMIM #613497). LAL hydrolyses cholesteryl esters and triglycerides in lysosomes and, as a consequence, dysfunction of this enzyme leads to accumulation of cholesteryl esters and triglycerides in, among others, hepatocytes, intestines and adrenal glands [1] . Depending on the residual LAL activity, LAL deficiency can result in the very severe and lethal Wolman disease or the late onset cholesteryl ester storage disease (CESD) [1] . CESD is typically characterized by hepatosplenomegaly and type IIb hyperlipidemia [2] . Recently, we identified 3 siblings with a clinical diagnosis of familial hypercholesterolemia (FH; type IIa hyperlipidemia) that were homozygous for a mutation in LIPA [3, 4] . At physical examination hepatosplenomegaly was not observed. It has been suggested that CESD should be considered as a differential diagnoses in patients with clinical FH in whom no FH mutation is identified [5] . Based on the potential overlap, CESD might be underdiagnosed [4, 6] . The current standard of care for dyslipidemia in patients with CESD is treatment with 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibitors (statins) [6] . However, reduction of plasma LDL-C levels in these patients might potentially lead to increased intra-cellular levels of cholesteryl esters, which may worsen the effects on liver function [6] . Recently, Burton and co-workers showed that enzyme replacement therapy (ERT; sebelipase alpha; Kanuma ® ) normalized alanine aminotransferase levels and decreased hepatic fat content in CESD patients, compared with placebo [7] . Since December 2015, sebelipase alfa has been approved by the US Food and Drug Administration (FDA) for treatment of patients with LAL deficiency. It has been suggested that screening for LIPA mutations in phenotypically diagnosed FH patients without mutations in LDLR, APOB, and PCSK9, might identify CESD patients who might be eligible for ERT by sebelipase alfa. Therefore, we aimed to establish the prevalence of LIPA mutations in patients with clinically, but not genetically defined FH.
Patients and methods
The study cohort comprised patients with a clinical FH phenotype in whom, after genetic analysis by Sanger sequencing, no mutations had been identified in LDLR (OMIM #606945) or APOB (OMIM #107730). LDLR was also analysed by MLPA (Multiplex ligation-dependent probe amplification) to detect major gene rearrangements. The genetic studies were performed by the national referral laboratory for DNA diagnostics of inherited dyslipidemias at the Academic Medical Center of the University of Amsterdam, the Netherlands. Given the low prevalence of mutations in LDLRAP (#605747), leading to Autosomal Recessive Hypercholesterolemia, and PCSK9 (OMIM #607786), causing an FHlike phenotype termed Autosomal Dominant Hypercholesterolemia, sequencing of these genes was only performed when homozygous FH was suspected (for LDLRAP) or when patients fulfilled the criteria for FH as published by Civeira and co-workers [8] . Individuals with a secondary form of dyslipidemia or an LDL-C level below the 95th percentile for age and gender were excluded. Genetic analysis of LIPA was performed by direct Sanger sequencing using Big Dye Terminators (ABI Prism V1.1) and products were run on a Genetic Analyzer 3730 (Applied Biosystems, Foster City,CA). Sequence data was analysed by the Sequencer package (GeneCodes Co, Ann Arbor, MI). All identified variants were assessed for pathogenicity using a literature search in PubMed and in silico prediction models including SIFT/PROVEAN, PolyPhen2 and MutationTaster. The LIPA transcript NM_000235.3 was used throughout all databases and in silico prediction models.
From all study subjects written informed consent was obtained, allowing genetic analysis to determine the cause of inherited dyslipidemias.
Results
We selected 276 patients (213 adults and 63 children) with a phenotypic diagnosis of FH of whom 105 (38.0%) were male. The mean age (±SD) of included patients was 53.3 ± 11.4 and 10.6 ± 3.7, for adults and children, respectively (Table 1) . Mean LDL-C levels were 7.8 ± 1.3 mmol/L and 4.4 ± 1.5 mmol/L, respectively. A total of 21 variants were identified of which 16 were previously described (see rs number in Table 2 ). Six patients were found to be heterozygous carriers of a potentially pathogenic mutation. Two patients were carriers of c.683 T > C in exon 7, encoding a phenylalanine to serine amino acid substitution (p.Phe228Ser) that was predicted to be pathogenic by all in silico prediction models used. Two patients were carriers of the c.894G > A mutation in exon 8 (p.Gln298Gln) which is a common synonymous but pathogenic variant among LAL deficiency patients, affecting the splice site at the end of exon 8 (ClinVar RCV000185528.3) [9] . One patient was carrier of c.913 T > A in exon 9, causing a phenylalanine to isoleucine substitution (p.Phe305Ile) that was predicted to be potentially pathogenic by PolyPhen2, and one patient was carrier of c.966 þ 3 A > T, affecting a splice site, to a similar extent as is predicted for the known functional p.Gln298Gln variant in exon 8. Homozygous or compound heterozygous carriers of (potentially) pathogenic LIPA mutations were not identified.
Discussion
In this study we aimed to determine the prevalence of homozygosity for LIPA mutations among individuals who were clinically diagnosed with FH, but not genetically confirmed. We identified 5 Table 1 Clinical characteristics of included patients.
Age, years ± SD 10.6 ± 3. heterozygous LIPA mutation carriers. No homozygous or compound heterozygous carriers of (potentially) pathogenic mutations were identified, which shows that LAL deficiency was not missed as diagnosis in our study population. Recently, Pullinger and co-workers investigated the frequency of a common LIPA mutation in 1357 patients with various types of dyslipidemia. In this study, six individuals were found to be heterozygous carriers of c.894G > A of whom two had isolated elevated LDL-C levels. After sequencing the heterozygous individuals for other LIPA mutations, one patient with combined dyslipidaemia (elevated LDL-C, elevated triglycerides, and low high density lipoprotein cholesterol levels) was found to be a compound heterozygous LIPA mutation carrier. In line with our results, no homozygous LIPA mutation carriers were identified among individuals with isolated elevated LDL-C levels [10] .
The overall prevalence of LAL deficiency has been estimated to vary between 1 in 40,000 to 1 in 300,000 individuals [6] . While applying the Hardy Weinberg Equilibrium, one would expect to identify at least one heterozygous LIPA mutation carrier in 100e274 individuals. The fact that we identified 5 heterozygous carriers in 276 individuals with heterozygous FH might imply that the FH population is relatively enriched with LIPA mutation carriers and we might have missed LAL deficiency patients due to the relatively small study population. This would be in line with the previous identification of a family with three LAL deficiency patients with a clear FH phenotype [4] and underlines the importance of genetic testing for rare diseases in case clinical phenotypes may overlap the phenotype of more prevalent disorders. While considering the diagnosis of LAL deficiency it is, however, of great importance to notice that LAL deficiency is an autosomal recessive disease while FH due to mutations in LDLR, APOB or PCSK9 is autosomal dominant. Moreover, it has been shown that heterozygous LIPA mutation carriers (eg. the parents of a patient with LAL deficiency) generally do not demonstrate a hypercholesterolemic phenotype [3] . Therefore, it seems reasonable to make a distinction between the diseases based on a thorough clinical assessment, including an extensive family history and determination of the lipid profiles of the parents or children of an index case, rather than performing genetic testing for LIPA mutations in all patients with an FH phenotype without a mutation in LDLR, APOB or PCSK9.
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